Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China Meheco Group CoSHSE:600056 -0.31%69 Debt-to-EBITDA is 4.00 as of Mar. 2026, which is 80% above its 10-year median of 2.22. GuruFocus rates SHSE:600056 with a GF Score™ of 69/100 and a GF Value™ of ¥10.46 (Fairly Valued). The stock has 6 warning signs investors should review. Among 91 Medical Distribution companies, China Meheco Group Co ranks worse than 76.92% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for China Meheco Group Co's Debt-to-EBITDA or its related term are showing as below:
SHSE:600056'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.29 Med: 2.22 Max: 4.64
Current: 4.64
During the past 13 years, the highest Debt-to-EBITDA Ratio of China Meheco Group Co was 4.64. The lowest was 0.29. And the median was 2.22.
SHSE:600056's Debt-to-EBITDA is ranked worse than 76.92% of 91
companies
in the Medical Distribution industry
Industry Median: 2.29
vs SHSE:600056: 4.64
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
China Meheco Group Co Debt-to-EBITDA Related Terms
China Meheco Group Co Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for China Meheco Group Co's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:600056 vs MCK, COR, CAH: Debt-to-EBITDA Comparison
For the Medical Distribution subindustry, China Meheco Group Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Meheco Group Co Debt-to-EBITDA vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, China Meheco Group Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where China Meheco Group Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
China Meheco Group Co (SHSE:600056) has a Debt-to-EBITDA of 4.00 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on China Meheco Group Co. This is 80% above median its historical median of 2.22. Over the past decade, China Meheco Group Co's Debt-to-EBITDA has ranged from 0.29 to 4.64. According to the industry distribution chart, China Meheco Group Co ranks #70 out of 91 companies in the Medical Distribution industry, placing it in the top 76.9%.
Is China Meheco Group Co's Debt-to-EBITDA too high?
China Meheco Group Co's current Debt-to-EBITDA of 4.00 is 80% above median its 10-year median of 2.22. Over the past 10 years, this metric has ranged from a low of 0.29 to a high of 4.64. The Medical Distribution industry median Debt-to-EBITDA is 2.29. China Meheco Group Co's value of 4.00 is 74.7% above this industry median. Based on the distribution chart, China Meheco Group Co ranks #70 out of 91 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, China Meheco Group Co has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does China Meheco Group Co's Debt-to-EBITDA compare to MCK and COR?
According to the Medical Distribution industry distribution chart, China Meheco Group Co ranks #70 out of 91 companies for Debt-to-EBITDA. This places China Meheco Group Co in the lower half of its industry. The industry median Debt-to-EBITDA is 2.29. China Meheco Group Co's value of 4.00 is 74.7% above this benchmark. Historically, China Meheco Group Co's own Debt-to-EBITDA has ranged from 0.29 to 4.64 over the past decade. While the company's 10-year median is 2.22 vs. the industry median of 2.29, China Meheco Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Distribution company?
The median Debt-to-EBITDA among Medical Distribution companies is 2.29, based on 91 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Meheco Group Co's current Debt-to-EBITDA of 4.00 is 74.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on China Meheco Group Co. For the Medical Distribution industry, the median Debt-to-EBITDA is 2.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Meheco Group Co's current Debt-to-EBITDA is 4.00, which is 80% above median its own 10-year median of 2.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Meheco Group Co stock overvalued right now?
Based on GuruFocus' analysis, China Meheco Group Co (SHSE:600056) is currently considered Fairly Valued. The stock's GF Value™ is ¥10.46, compared to a current price of ¥9.50 — trading 9.2% below its estimated fair value. The current Debt-to-EBITDA is 4.00, which is 80% above median its 10-year median of 2.22 and 74.7% above the Medical Distribution industry median of 2.29. China Meheco Group Co's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For China Meheco Group Co (SHSE:600056), the current Debt-to-EBITDA is 4.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Meheco Group Co (SHSE:600056) Overvalued in 2026?
Based on GuruFocus' analysis, China Meheco Group Co stock appears to be undervalued.
The current stock price of ¥9.50 is trading 9.2% below its estimated GF Value™ of ¥10.46.
GuruFocus considers China Meheco Group Co to be Fairly Valued.
Key valuation signals for SHSE:600056:
Debt-to-EBITDA: 4.00 (80% above median its 10-year median of 2.22)
GF Value™: ¥10.46 vs. price of ¥9.50 (9.2% below fair value)
Industry Position: 74.7% above the Medical Distribution median (#70 of 91)
No single metric tells the full story. See the SHSE:600056 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Meheco Group Co Ltd is engaged in the distribution and trading of botanical medicines, medical instruments, and pharmaceuticals. It offers botanic medicines and herbal products, as well as exports of natural medicines, including herbs, spices, plant extracts, bee products, and Chinese traditional medicines. The company's business scope covers the whole industry chain, from research and development, cultivation and processing, manufacturing, distribution, and logistics to international trading, academic promotion, and technical service. The corporation provides trading services for customers in the pharmaceutical and chemical field, covering APIs, preparations, biologicals, blood products, and others.
69GF Score
Get the complete analysis for SHSE:600056
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600056 has been successfully added to your 
